Protocol Ledger

NCT07699939 · Phase II · RECRUITING

Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction Adenocarcinoma

Interventional Phase II clinical trial protocol NCT07699939 sponsored by National Cancer Center, Japan in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-07-15 Enrollment: 136 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07699939
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)136 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07699939
Protocol FieldVerified Registry Value
NCT IdentifierNCT07699939
Consolidated Lead SponsorNational Cancer Center, Japan
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment136 participants (ESTIMATED)
Registered Start Date2026-07-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07699939
Hospital Research SiteLocationSite Profile
Chiba Cancer CenterChiba, JapanOpen Hospital Dossier ->
Hiroshima University HospitalHiroshima, JapanOpen Hospital Dossier ->
Osaka International Cancer InstituteOsaka, JapanOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI